ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Celgene Acquires Genomics Specialist …

by Rick Mullin
May 4, 2015 | APPEARED IN VOLUME 93, ISSUE 18

Celgene will acquire Quanticel Pharmaceuticals, a privately held specialist in cancer drug discovery. The deal will give Celgene access to Quanticel’s platform for the single-cell genomic analysis of human cancer as well as Quanticel’s lead programs targeting specific epigenetic modifiers. The deal caps a 2011 collaboration between the companies, during which time Quanticel generated several drug candidates expected to begin clinical trials next year. Celgene will pay $100 million for Quanticel plus milestone payments of up to $385 million.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment